![](bg9.png)
Sandra Carvalho from the Anatomical Pathology Service. This work was supported
by CIISA and FCT (SFRH/BD/70720/2010).
References
1. De Maria R., Olivero M., Iussich S., Nakaichi M., Murata T. Bartolomeo B. and Di Renzo
M.F.. (2005). Spontaneous feline mammary carcinoma is a model of HER2 overexpressing
poor prognosis human breast cancer. Cancer Research, 65, 907-912.
2. Gancberg D., Järvinen T., Leo A., Rouas G., Cardoso F., Paesmans M., Verhest A., Piccart
M., Isola J. and Larsimont D. (2002). Evaluation of HER-2/NEU protein expression in
breast cancer by immunohistochemistry. Breast Cancer Research and Treatment, 74, 113–
120.
3. Martin de las Mulas, J., Van Niel M., Millán, Y., Blankenstein M.A., Van Mil F. and
Misdorp W. (2000). Immunohistochemical analysis of estrogen receptors in feline
mammary gland benign and malignant lesions: comparison with biochemical assay.
Domestic Animal Endocrinology, 18, 111–125
4. Martin de las Mulas, J., Van Niel M., Millán, Y., Ordás J., Blankenstein M.A., Van Mil F.
and Misdorp W. (2002). Progesterone receptors in normal, dysplastic andtumourous feline
mammary glands. Research in Veterinary Science, 72, 153-161.
5. Ménard S., Tagliabue E., Campiglio M. and Pupa S.M. (2000). Role of HER2 Gene
Overexpression in Breast Carcinoma. Journal of Cellular Physiology, 182, 150–162.
6. Millanta F., Calandrella M., Citi S., Della Santa D. and Poli A. (2005). Overexpression of
HER-2 in feline invasive mammary carcinomas. Veterinary Pathology, 42, 30-34.
7. Misdorp W., Else R.W., Hellmen E. and Lipscomb T.P. (1999). Histologic Classification of
Mammary Tumors of the Dog and the Cat. Armed Force Institute of Pathology and World
Health Organization. Washington, DC.
8. Ordás J., Millán Y., Dios R., Reymundo C. and de Las Mulas J.M. (2007). Proto-oncogene
HER-2 in normal, dysplastic and tumorous feline mammary glands. BMC Cancer, 7(179).
9. Press M., Slamon D., Flom K., Park J., Zhou J. and Bernstein L. (2002). Evaluation of
HER-2/neu Gene Amplification and Overexpression. Journal of Clinical Oncology, 20,
3095-3105.
10. Rasotto R., Caliari D., Castagnaro M., Zanetti R. and Zappulli V. (2011). An
Immunohistochemical Study of HER-2 Expression in FMC. Journal Comparative
Pathology, 144, 170-179.
11. Sáez A., Andreu F.J., Seguí M.A., Baré M.L., Fernández S., Dinarés C. and Rey M. (2006).
HER-2 gene amplification by CISH compared FISH. The Breast, 15, 519-527.
12. Stebbing J., Copson E. and O’Reilly S. (2000). Herceptin (trastuzamab) in advanced breast
cancer. Cancer Treatment Reviews, 26, 287-290.
13. Thomson T., Hayes M., Spinelli J., Hilland E., Sawrenko C., Phillips D., Dupuis B. and
Parker R. (2001). HER-2/neu in Breast Cancer. Modern Pathology, 14 (11), 1079-1086.
14. Winston J., Craft D.M., Scase T.J. and Bergman P.J. (2005). Immunohistochemical
detection of HER-2/neu expression in spontaneous feline mammary tumours. Veterinary
and Comparative Oncology, 3, 8-15.
15. Withrow, S. J. and Vail, D. M. (2007). Withrow & MacEwen's Small Animal Clinical
Oncology. (4
th
Ed.). Saunders, Philadelphia: Elsevier Inc.
16. Wolff A.C., Hammond E.H., Schwartz J.N., Hagerty K.L., Allred D.C., et al. (2007).
ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2
testing in breast cancer. Journal of Clinical Oncology, 25(1), 118-45.
17